Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern

Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern

Objectives. To report on a novel IIF pattern specifically associated with antibodies to DNA topo I. Methods. A novel compound IF pattern, designated Scl-70 pattern, was characterized in routine ANA-HEp-2 IIF screening. Within the last 3 years, all serum samples presenting the Scl-70 pattern at the A...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2009-06, Vol.48 (6), p.632-637
Main Authors: Dellavance, Alessandra, Gallindo, Cristiane, Soares, Mariana Guanaes, da Silva, Neusa Pereira, Mortara, Renato Arruda, Andrade, Luís Eduardo Coelho
Format: Article
Language:eng
Subjects:
Anti-nuclear antibodies
Autoantibodies
Autoantibodies - immunology
Autoantigens - blood
Basic Science
Biological and medical sciences
Cell Line
Cell Nucleolus - chemistry
Cell Nucleus - chemistry
Chromosomes - chemistry
Cytoplasm - chemistry
Diseases of the osteoarticular system
DNA topoisomerase I
DNA Topoisomerases, Type I - immunology
Fluorescent Antibody Technique, Indirect
Humans
Interphase
Medical sciences
Mitosis
Nuclear Proteins - blood
Nucleolus Organizer Region - chemistry
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scl-70
Scleroderma, Systemic - immunology
Systemic sclerosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. To report on a novel IIF pattern specifically associated with antibodies to DNA topo I. Methods. A novel compound IF pattern, designated Scl-70 pattern, was characterized in routine ANA-HEp-2 IIF screening. Within the last 3 years, all serum samples presenting the Scl-70 pattern at the ANA-HEp2 IIF screening were tested for anti-topo I reactivity. Conversely, 16 serum samples with known anti-topo I reactivity and affinity-purified anti-topo I antibody preparations were tested for the Scl-70 pattern. Results. The Scl-70 pattern comprised the staining of five cellular regions: nucleus, nucleolus and cytoplasm in interphase cells; nucleolar organizing region (NOR) and chromosomes in mitotic cells. All 81 serum samples selected as Scl-70 pattern reacted with topo I. All 16 anti-topo I samples and antibody preparations reproduced the Scl-70 pattern. This compound IF pattern was consistently observed in different commercial HEp-2 cell slides and in home-made slides with HEp-2 cells and human fibroblasts fixed with alternative protocols. Double IIF experiments demonstrated the co-localization of topo I and human upstream binding factor at the NOR. Conclusions. The Scl-70 pattern belongs to the group of compound IF patterns that hold strong association with the respective autoantibody specificities, such as that observed with centromere protein F (CENP-F) and nuclear mitotic apparatus-1 (NuMA-1) protein. The identification of the Scl-70 pattern at routine ANA-HEp-2 IIF screening may lead to implementation of specific tests for the identification of anti-topo I antibodies. In addition, the Scl-70 pattern outlines cellular domains other than those previously reported for topo I, which is of interest for further understanding the roles of this enzyme in cell biology.
ISSN:1462-0324
1462-0332